The short version of GHRH fits in a sentence. The long version — which is the one that helps — is below.
Reviewed 2026-04-04. Anything still debated is marked as such rather than presented as settled.
CJC-1295 is a synthetic peptide analog of growth hormone-releasing hormone, constructed on the 29-amino-acid fragment designated GRF(1-29). The name began as an internal development code during the 1990s and later spread through research supply catalogs and discussion forums. The molecule does not occur in nature; its sequence is engineered rather than isolated from tissue. Two related compounds are sold under this single label, and they differ by one appended chemical group that strongly influences how long the peptide remains in circulation.
The dividing feature between the two forms is a maleimide-based drug affinity complex, abbreviated DAC. In the DAC-bearing version, a linker attaches the peptide to serum albumin after administration, and that association slows removal from plasma. The version lacking DAC appears in catalogs as MOD GRF(1-29) or tetrasubstituted GRF(1-29). Because informal writing treats both as one item, comparisons drawn from such sources routinely blend measurements taken from two molecules with substantially different behavior.
Identity and purity are assessed mainly by reversed-phase high-performance liquid chromatography combined with mass spectrometry. The chromatographic separation resolves the target peptide from truncation products and from species carrying oxidised residues, while mass measurement confirms the expected molecular mass. Because the two common variants differ by roughly 280 daltons, a mass determination distinguishes them unambiguously. Purity is often quoted as a percentage of total peak area, although that figure depends on the detection wavelength and the integration method applied.
Reported half-lives differ widely between the two variants and between species. Values for the albumin-binding form are usually expressed in days, while the unconjugated form is measured in minutes to a few hours. Sampling schedules, assay sensitivity, and route of administration all influence the numbers, which limits direct comparison across studies. Whether sustained receptor occupancy produces different downstream effects from pulsatile stimulation remains an open question in the published work. Claims about relative potency should therefore be read alongside the specific study design that produced them.
Lyophilised powder is the usual supplied form. The material is hygroscopic, so vials are typically equilibrated to room temperature before opening in order to prevent condensation on the contents. Long-term storage is generally described at minus twenty degrees Celsius or colder, protected from light and moisture. Repeated freeze-thaw cycles are avoided because they promote aggregation and loss of soluble material. A reconstituted solution is considerably less stable than the dry powder and is normally kept refrigerated for short periods only.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Analog of growth hormone-releasing hormone |
| Chain length | 29 amino acids | Based on the GRF(1-29) fragment |
| Appearance | White to off-white lyophilized powder | Common research supply form |
| Solubility | Soluble in water and aqueous buffers | Powder requires reconstitution before use |
| Typical storage | −20 °C or below | Kept away from light and moisture |
CJC-1295 is a synthetic peptide designed to mimic growth hormone-releasing hormone (GHRH), the endogenous signal that prompts the pituitary gland to release growth hormone. The compound is a modified fragment of the natural hormone, spanning the first twenty-nine amino acids of GHRH with several substitutions that slow enzymatic breakdown. Two variants circulate in research settings: one carrying a drug affinity complex (DAC) and one without it. The DAC-free form is frequently labelled Mod GRF(1-29) in catalogs and discussion forums.
The peptide binds GHRH receptors on somatotroph cells within the anterior pituitary, triggering a signalling cascade that increases growth hormone secretion. Its improved resistance to dipeptidyl peptidase IV degradation distinguishes it from the parent hormone. In the DAC-bearing version, a maleimide group reacts with a cysteine residue on serum albumin, forming a covalent bond that keeps the peptide in circulation far longer. That albumin attachment is the central design feature separating the two research variants.
Pharmacokinetic behaviour differs sharply between the two forms. The DAC-bearing peptide shows an extended circulation time measured in days, whereas the version without the complex is cleared within roughly half an hour. This gap shapes how researchers design dosing schedules in animal models. Whether the prolonged presence of the DAC form produces effects meaningfully different from the short-acting variant remains an open question, since comparative human data are scarce.
CJC-1295 belongs to a class of synthetic peptides modeled on growth hormone releasing hormone, a forty-four amino acid signal produced by the hypothalamus. The compound is built from the first twenty-nine residues of the natural sequence, with four substitutions introduced at positions 2, 8, 15 and 27. These changes were designed to slow enzymatic breakdown while preserving receptor activation. The result is a peptide that is shorter than native GHRH and considerably more resistant to ordinary clearance pathways in circulation.
Two related forms appear under the CJC-1295 name. The simpler analogue, commonly written as modified GRF(1-29), carries the four substitutions but no additional conjugation. The second form attaches a maleimidopropionic acid linker to a lysine residue, a modification frequently called the drug affinity complex. That linker reacts with the free thiol on serum albumin to form a covalent bond. Because albumin has a long residence time in blood, the conjugated peptide stays in circulation far longer than the unconjugated analogue.
Receptor level activity follows the canonical GHRH pathway. The peptide binds the GHRH receptor, a class B G protein coupled receptor on somatotroph cells of the anterior pituitary. Binding raises intracellular cyclic AMP, which promotes calcium entry and the release of growth hormone into the bloodstream. Because the molecule acts at the same receptor as the endogenous hormone, its effect is superimposed on the natural pulsatile rhythm rather than replacing it. Whether sustained receptor occupation leads to desensitization is not fully settled.
=== Specificity === The ATPase activity of TAP is highly dependent on the presence of the correct substrate, and peptide binding is prerequisite for ATP hydrolysis. This prevents waste of ATP via peptide-independent hydrolysis. The specificity of TAP proteins was first investigated by trapping peptides in the ER using glycosylation. TAP binds to 8- to 16-residue peptides with equal affinity, while translocation is most efficient for peptides that are 8 to 12 residues long. Efficiency reduces for peptides longer than 12 residues. However, peptides with more than 40 residues were translocated, albeit with low efficiency. Peptides with low affinity for the MHC class I molecule are transported out of the ER by an efficient ATP-dependent export protein. These outlined mechanisms may represent a mechanism for ensuring that only high-affinity peptides are bound to MHC class I.
== Invertebrates == In some invertebrates, such as Porifera, Cnidaria, Ctenophora, and some triploblasts (namely the acoelomates), the term "mesenchyme" refers to a more-or-less solid but loosely organized tissue that consists of a gel matrix (the mesoglea) with various cellular and fibrous inclusions, located between the epidermis and the gastrodermis (non-triploblast animals usually are considered to lack "connective" tissue). In some cases, the mesoglea is noncellular.
== Further reading == Carson C, Faria G, Hellstrom WJ, Krishnamurti S, Minhas S, Moncada I, et al. (1 January 2010). "Implants, Mechanical Devices, and Vascular Surgery for Erectile Dysfunction". Journal of Sexual Medicine. 7 (1). Wiley: 501–523. doi:10.1111/j.1743-6109.2009.01626.x. PMID 20092450.
=== „Sozusagen Paris“ (2016) === „Sozusagen Paris“' (Paris, So to Speak) constitutes a sequel to the previous novel: after a public reading from „Love Writ Large“, the first-person narrator is approached by his childhood sweetheart, who is now the mayor of a small town. This sequel describes the first encounter between the two characters after thirty years, which lasts from the moment of their reunion after the public reading until the next morning. Overall, the text complements its predecessor: whereas the former dealt with the ecstasy of first love, the latter focuses on long-term love, specifically in light of Jutta's 23-year marriage. Whereas „Love Writ Large“ was told from the man's perspective, the nighttime conversation in Paris, So to Speak is shaped by the woman’s point of view —for the first time in Kermani's work, a female voice is at the center of the text. Like „Love Writ Large, Paris So to Speak“ also aims at a supra-individual exploration of love, but it is anchored differently: instead of early Islamic mysticism, it’s the French marriage novels of the nineteenth century up to Marcel Proust which serve as a foil here for modern love. This shifts the reflection on love from a general anthropological to a historical perspective. In particular, the important role of their children to the couple's life, lifestyle, and emotional stability serves to emphasize distinctions from older marriage novels and to highlight specifics of love and cohabitation in the 21st century.
Sources: en.wikipedia.org
Their goal was to discover novel non-steroidal mineralocorticoid receptor antagonists for use as efficacious and safe drugs with the pharmacodynamics and pharmacokinetics well defined. Their goal was to use these candidates for a broad spectrum of diseases. This was essentially the third wave. The first mineralocorticoid receptor antagonists were all discovered and identified by in vivo experiments whereas the identification of novel non-steroidal mineralocorticoid receptor antagonists were done with high-throughput screening of millions of chemical compounds in various pharmaceutical companies.
Dyck, Peter J.; Overland, Carol J.; Low, Phillip A.; Litchy, William J.; Davies, Jenny L.; Dyck, P. James B.; O'Brien, Peter C. (August 2010). "Signs and symptoms versus nerve conduction studies to diagnose diabetic sensorimotor polyneuropathy: Cl vs. NPhys trial: Cl vs. NPhys Trial". Muscle & Nerve. 42 (2): 157–164. doi:10.1002/mus.21661. PMC 2956592. PMID 20658599. Vitale, G.I.; Quatrale, R.P.; Giles, P.J.; Birnbaum, J.E. (July 1986). "Electrical field stimulation of isolated primate sweat glands". British Journal of Dermatology. 115 (1): 39–47. doi:10.1111/j.1365-2133.1986.tb06218.x. PMID 3524654. S2CID 23529777. Freedman, Barry I.; Bowden, Donald W.; Smith, Susan Carrie; Xu, Jianzhao; Divers, Jasmin (January 2014). "Relationships between electrochemical skin conductance and kidney disease in Type 2 diabetes". Journal of Diabetes and Its Complications. 28 (1): 56–60. doi:10.1016/j.jdiacomp.2013.09.006. PMC 3877197. PMID 24140119. Ramachandran, Ambady; Moses, Anand; Shetty, Samith; Thirupurasundari, Chandragiri Janakiraman; Seeli, Abraham Catherin; Snehalatha, Chamukuttan; Singvi, Sunil; Deslypere, Jean-Paul (June 2010). "A new non-invasive technology to screen for dysglycaemia including diabetes". Diabetes Research and Clinical Practice. 88 (3): 302–306. doi:10.1016/j.diabres.2010.01.023. PMID 20188429. Raisanen, Anu; Eklund, Jyrki; Calvet, Jean-Henri; Tuomilehto, Jaakko (June 2014). "Sudomotor Function as a Tool for Cardiorespiratory Fitness Level Evaluation: Comparison with Maximal Exercise Capacity". International Journal of Environmental Research and Public Health.
== Shape-memory PEEK in biomechanical applications == PEEK is not traditionally a shape-memory polymer; however, recent advances in processing have allowed shape-memory behaviour in PEEK with mechanical activation. This technology has expanded to applications in orthopaedic surgery.
Sources: en.wikipedia.org
Pennyroyal is toxic to humans and has differing effects dependent on the volume and concentration ingested. The most concentrated and toxic form of the pennyroyal plant is pennyroyal oil. The oil contains pulegone (a cyclohexanone), the molecule found in the highest concentration (80-92%) in the pennyroyal plant. Pulegone causes a variety of ailments in those who ingest it and is what causes the plant to have its peppermint flavor. Symptoms that may persist after ingesting a small dose (<10 mL) of pennyroyal oil are nausea, vomiting, abdominal pain and dizziness. Larger volumes may result in multiorgan failure that could lead to death. There are no current toxicokinetics studies performed on humans for the effects of pulegone, but there are some studies performed on other mammals. When pulegone is ingested, it is broken down by the liver and reacts to form multiple toxic metabolites that can wreak havoc in the body. Some identified metabolites are menthofuran, piperitenone, piperitone, and menthone. As little as 10 mL of pennyroyal oil ingestion was associated with moderate to severe hepatic toxicity.
== Content == The Code contains both mandatory regulations and recommended provisions, setting out the minimum stability standards for ships. This includes information on precautions against capsizing, metacentric heights (GM), righting levers (GZ), rolling criteria, Free surface effect and watertight integrity. The 2008 version of the Code details guidelines on Second Generation Intact Stability for ships, specifically criteria for dynamic stability and damage assessment. The Code is split into two parts. Part A contains mandatory criteria. Part B contains additional guidelines and recommendations. The Code requires each ship to have a stability book on the ship. For passenger ships, a regular survey is required.
=== Designed proteins === Numerous protein structures are the result of rational design and do not exist in nature. Proteins can be designed from scratch (de novo design) or by making calculated variations on a known protein structure and its sequence (known as protein redesign). Rational protein design approaches make protein-sequence predictions that will fold to specific structures. These predicted sequences can then be validated experimentally through methods such as peptide synthesis, site-directed mutagenesis, or Artificial gene synthesis.
Sources: en.wikipedia.org
No. It is a laboratory-synthesized analog built on a fragment of the natural hormone. The natural peptide is shorter-lived and lacks the stabilizing substitutions found in the synthetic version.
DAC stands for drug affinity complex, a chemical group that binds the peptide to serum albumin. The binding slows clearance and lengthens the time the molecule stays in plasma compared with the unmodified analog.
Because two distinct molecules are discussed under one informal label. The albumin-binding version clears over several days, while the form without that group clears within roughly half an hour. Mixing results from both creates inconsistent figures.
Chromatography reports how much material elutes as a single peak but does not confirm what that material is. Mass spectrometry supplies the molecular mass, which is characteristic of a given sequence and its modifications. Together the two methods support both a purity figure and an identity claim.